

BERENBERG CONFERENCE USA 2022.

23 & 24 MAY






PRESENTING EUROPE'S LEADING CUSTOMER-CENTRIC E-PHARMACY PLATFORM.







SHOP APOTHEKE EUROPE AT A GLANCE.

COMBINING OTC, BPC & RX OFFERINGS.

SERVING ALL AGE GROUPS.

LEADERSHIP POSITION IN EUROPE.


7 COUNTRIES.


8,3 MILLION CUSTOMERS.

> 1,800 EMPLOYEES.

> 1 B € SALES 2021.

OFFICE HUBS IN SEVENUM, COLOGNE. BERLIN, MUNICH, WARSAW AND MILAN.








OUR GOAL.






SIGNIFICANT OPPORTUNITY.



1 Source: Arizton Advisory & Intelligence; 2 Source: Research and Markets (2019); 3 Source: Statista



THE GOLD STANDARD FOR CUSTOMER EXPERIENCE.







Improving customer experience based on our state-of-the-art technology platform is a key competitive advantage of our business model.



OUR COMPETITIVE ADVANTAGE. RUNNING RELEVANT DIGITAL TECHNOLOGY IN-HOUSE.

- Possibility to quickly respond to latest developments in e-commerce.
- Rapid deployment of new features to further improve customer experience.
- Fast and secure connectivity of partner systems.



OFFERING A WORLD OF HEALTH TO EVERYONE.



A GOOD FOUNDATION FOR: INTACT LONG-TERM GROWTH PROSPECTS.





FUNCTIONAL FOOD AND NUTRITION



OWN BRANDS

OTC













THE E-RX OPPORTUNITY IN GERMANY.






E-PRESCRIPTION PROGRESS & OUTLOOK.



- 30,000 e-prescriptions have to be processed during the test phase before broader rollout; half-way mark passed in May.
- Details of rollout to be decided and announced following Gematik shareholders' meeting at the end of May 2022.
- Shop Apotheke Europe is ready for e-prescriptions and has been processing them successfully since October 2021.
- We recently strengthened our preparedness for the rollout by acquiring quick-commerce delivery business FIRST A.







LATEST NEWS FROM MSCI.

- IMPROVEMENT IN THESE SCORES:
 - PRODUCT CARBON FOOTPRINT,
 - PRIVACY & DATA SECURITY,
 - PRODUCT SAFETY & QUALITY,
 - GOVERNANCE,
 - LABOR MANAGEMENT.
- INCREASED FROM 5.0 POINTS TO 8.1 POINTS.

UPGRADED TO AA RATING.



APPENDIX.

HIGHLIGHTS.





DOUBLE-DIGIT GROWTH IN EVERYTHING-BUT-RX CONTINUES.

UP 15%, ON TRACK FOR FULL-YEAR GUIDANCE WITH SIGNIFICANT MARKET SHARE GAINS. RX SALES STABLE QUARTER-OVER-QUARTER.

• ADJ. EBITDA EUR -4M.

MARGIN AT -1.4%, 2.1 PP BETTER THAN PRIOR Q4. ON TRACK FOR FULL YEAR GUIDANCE – OFFSETTING IMPACT OF A MORE CHALLENGING ENVIRONMENT.

• OPERATING CASH FLOW EUR +24M.

CONTINUED FAVOURABLE WORKING CAPITAL MOVEMENTS.

RECORD CUSTOMER SATISFACTION AND HIGH GROWTH OF NEW CUSTOMERS CONTINUED.

NPS 73, DRIVEN BY SUCCESSES FROM OUR NEW FACILITY. ACTIVE CUSTOMER BASE 8.3M: UP 0.4M IN Q1 AND 1.5M YOY.


• E-RX GEMATIK TEST ACCELERATES.

APPROACHING 50% OF THE REQUIRED 30,000 SUCCESSFUL ORDERS.

ACQUISITION OF QUICK-COMMERCE FIRST A. DELIVERY WITHIN 30 MINUTES IN COOPERATION WITH LOCAL PHARMACIES.



KEY FINANCIALS. DACH / EVERYTHING-BUT-RX +10%, INTERNATIONAL UP +30%.





KEY FINANCIALS. 2021: EUR 1,060M SALES AND EUR -5M (-0.5%) ADJ. EBITDA.

Adjusted numbers in million of euros	Q1 2022			Full Year 2021			
	Q1 2021	Q1 2022	Better/ (Worse)		2020	2021	Better/ (Worse)
Sales	284	305	7.3%		968	1,060	9.5%
- Everything-but-Rx (Non-Rx)	239	275	15%		749	917	22.5%
- Rx	45.1	30.4	(32.6%)		219	144	(34.6%)
Gross profit margin	25.6%	26.6%	1.0 рр		22.7%	25.2%	2.5 pp
Selling & distribution as percentage of sales	-20.7%	-25.0%	(4.3) pp		17.8%	-22.6%	(4.8) pp
Administrative costs as percentage of sales	-2.9%	-2.9%	0.0 pp		-2.7%	-3.1%	(0.4) pp
Adj. EBITDA	5.7	-4.3	(10)		22	-5	(27)
Adj. EBITDA margin	2.0%	-1.4%	(3.4) pp		2.2%	-0.5%	(2.7) pp
EBITDA	3.0	-10.5	(13.5)		15	-39	(54)

Adjustments in Q1 2022 EUR 6.2M: non-cash employee stock options costs, one-off external costs related to projects and acquisitions, EUR 4.3M from IFRS3 accounting of the business acquisitions in 2021.

Adjustments in 2021 EUR 33M: non-cash employee stock option costs, one-off costs related to projects which included the set-up of the new logistics centre and acquisition expenses, and EUR 22.45M from IFRS 3 accounting for the earn-out of the 2021 business acquisitions.



KEY FINANCIALS. ROBUST CASH POSITION.

